The benefits of clinical surveillance of LFS patients with known pathogenic mutations in TP53 are well established [9,10], therefore it is important to identify patients with LFS as rapidly as possible to offer appropriate cancer surveillance and prophylaxis management as well as to extend genetic testing to at-risk family members. Here, TP53 is linked to cancer.